Janus Henderson Global Life Sciences Fund
Fund
JFNNX
Price as of:
$69.73
+ $0.08
+ 0.11%
Primary Theme
fund company
Name
As of 12/16/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
6.8%
1 yr return
9.9%
3 Yr Avg Return
4.6%
5 Yr Avg Return
8.9%
Net Assets
$5.23 B
Holdings in Top 10
40.8%
52 WEEK LOW AND HIGH
$69.7
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 0.67%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 32.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000,000
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 12/16/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
JFNNX - Profile
Distributions
- YTD Total Return 6.8%
- 3 Yr Annualized Total Return 4.6%
- 5 Yr Annualized Total Return 8.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.09%
- Dividend Yield 0.5%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameJanus Henderson Global Life Sciences Fund
-
Fund Family NameJanus Henderson Funds
-
Inception DateDec 31, 1998
-
Shares OutstandingN/A
-
Share ClassN
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerAndrew Acker
Fund Description
The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Fund’s pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the “life sciences” sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. So, for example, companies with a “life science orientation” include companies engaged in research, development, production, or distribution of products or services related to health and personal care, medicine, or pharmaceuticals. The Fund implements its investment policies by investing primarily in equity securities of U.S. and foreign companies selected for their growth potential. The Fund normally invests in issuers from several different countries, which may include the United States. An issuer is deemed to be economically tied to a country or countries if one or more of the following tests are met: (i) the issuer is organized in, or its primary business office or principal trading market of its equity is located in, the country; (ii) a majority of the issuer’s revenues are derived from one or more countries; or (iii) a majority of the issuer’s assets are located in one or more countries. The Fund may, under unusual circumstances, invest in a single country. The Fund may invest in shares of companies through initial public offerings and private placements.Portfolio management applies a “bottom up” approach in choosing investments. In other words, portfolio management looks at companies one at a time to determine if a company is an attractive investment opportunity and if it is consistent with the Fund’s investment policies. In conducting the “bottom up” analysis, portfolio management considers factors including a company’s growth potential, the strength of a company’s management, and a company’s sustainable competitive advantages, returns on investment capital, and cash flow generation. Portfolio management also applies screens, which incorporate third-party inputs, to (i) seek to avoid investing in issuers that are United Nations Global Compact violators and (ii) seek to invest at least 80% of the Fund’s net assets, under normal circumstances, in issuers with an MSCI (or an equivalent third-party data provider, as determined by portfolio management) ESG rating of BB or higher.The Fund will generally consider selling a stock when, in portfolio management’s opinion, the stock shows declining fundamentals, its competitive advantages have deteriorated, or if the stock reaches its targeted value. The Fund will also consider selling a stock if, in portfolio management’s opinion, a superior investment opportunity arises.The Fund may seek to earn additional income through lending its securities to certain qualified broker-dealers and institutions on a short-term or long-term basis, in an amount equal to up to one-third of its total assets as determined at the time of the loan origination.
Read More
JFNNX - Performance
Return Ranking - Trailing
| Period | JFNNX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 6.8% | -24.7% | 22.0% | 35.22% |
| 1 Yr | 9.9% | -20.2% | 24.9% | 37.11% |
| 3 Yr | 4.6%* | -25.2% | 13.2% | 11.84% |
| 5 Yr | 8.9%* | -9.9% | 11.5% | 4.03% |
| 10 Yr | N/A* | -0.2% | 12.8% | 7.94% |
* Annualized
Return Ranking - Calendar
| Period | JFNNX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 2.9% | -12.6% | 19.0% | 52.83% |
| 2022 | -3.0% | -53.9% | 3.2% | 6.58% |
| 2021 | -3.0% | -39.6% | 24.2% | 63.82% |
| 2020 | 16.4% | -13.6% | 178.2% | 36.24% |
| 2019 | 21.5% | 3.8% | 63.8% | 44.36% |
Total Return Ranking - Trailing
| Period | JFNNX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 6.8% | -24.7% | 22.0% | 35.22% |
| 1 Yr | 9.9% | -20.2% | 24.9% | 37.11% |
| 3 Yr | 4.6%* | -25.2% | 13.2% | 11.84% |
| 5 Yr | 8.9%* | -9.9% | 11.5% | 4.03% |
| 10 Yr | N/A* | -0.2% | 12.8% | 6.98% |
* Annualized
Total Return Ranking - Calendar
| Period | JFNNX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 7.6% | -12.6% | 19.0% | 22.01% |
| 2022 | -2.6% | -53.9% | 3.7% | 13.16% |
| 2021 | 6.9% | -33.9% | 26.0% | 59.21% |
| 2020 | 25.7% | -0.7% | 180.6% | 37.58% |
| 2019 | 29.4% | 4.6% | 63.8% | 33.08% |
NAV & Total Return History
JFNNX - Holdings
Concentration Analysis
| JFNNX | Category Low | Category High | JFNNX % Rank | |
|---|---|---|---|---|
| Net Assets | 5.23 B | 6.43 M | 45.7 B | 13.84% |
| Number of Holdings | 114 | 25 | 430 | 20.13% |
| Net Assets in Top 10 | 2.33 B | 2.12 M | 23.9 B | 18.24% |
| Weighting of Top 10 | 40.76% | 18.4% | 78.1% | 76.73% |
Top 10 Holdings
- Eli Lilly Co. COM NPV 8.45%
- UnitedHealth Group Inc. COM USD0.01 6.85%
- Novo Nordisk A/S SER'B'DKK0.1 4.63%
- AstraZeneca PLC ORD USD0.25 3.65%
- AbbVie Inc. COM USD0.01 3.60%
- Amgen Inc. COM USD0.0001 3.24%
- Sanofi EUR2 2.77%
- Merck Co., Inc COM USD0.50 2.56%
- Boston Scientific Corporation COM USD0.01 2.52%
- Johnson Johnson COM USD1.00 2.48%
Asset Allocation
| Weighting | Return Low | Return High | JFNNX % Rank | |
|---|---|---|---|---|
| Stocks | 90.10% | 89.92% | 106.13% | 96.86% |
| Preferred Stocks | 2.08% | 0.00% | 7.86% | 10.69% |
| Convertible Bonds | 0.13% | 0.00% | 0.37% | 5.84% |
| Cash | 0.04% | 0.00% | 33.01% | 96.23% |
| Bonds | 0.01% | 0.00% | 12.39% | 27.67% |
| Other | 0.00% | -22.99% | 23.24% | 83.65% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | JFNNX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 36.36% |
| Utilities | 0.00% | 0.00% | 0.00% | 77.27% |
| Technology | 0.00% | 0.00% | 22.69% | 79.22% |
| Real Estate | 0.00% | 0.00% | 5.89% | 79.87% |
| Industrials | 0.00% | 0.00% | 7.02% | 79.87% |
| Financial Services | 0.00% | 0.00% | 1.60% | 84.42% |
| Energy | 0.00% | 0.00% | 0.00% | 77.27% |
| Communication Services | 0.00% | 0.00% | 9.11% | 79.87% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 80.52% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 79.22% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 83.77% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | JFNNX % Rank | |
|---|---|---|---|---|
| US | 78.37% | 61.27% | 104.41% | 82.39% |
| Non US | 11.74% | 0.00% | 34.10% | 26.42% |
Bond Sector Breakdown
| Weighting | Return Low | Return High | JFNNX % Rank | |
|---|---|---|---|---|
| Corporate | 13.28% | 0.00% | 81.57% | 16.67% |
| Cash & Equivalents | 0.04% | 0.00% | 100.00% | 85.53% |
| Derivative | 0.00% | -0.01% | 23.24% | 80.50% |
| Securitized | 0.00% | 0.00% | 0.00% | 74.64% |
| Municipal | 0.00% | 0.00% | 0.00% | 74.64% |
| Government | 0.00% | 0.00% | 29.44% | 75.36% |
Bond Geographic Breakdown
| Weighting | Return Low | Return High | JFNNX % Rank | |
|---|---|---|---|---|
| US | 0.01% | 0.00% | 11.75% | 27.67% |
| Non US | 0.00% | 0.00% | 3.33% | 79.25% |
JFNNX - Expenses
Operational Fees
| JFNNX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.67% | 0.08% | 4.48% | 79.25% |
| Management Fee | 0.64% | 0.03% | 1.25% | 42.14% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | 52.38% |
Sales Fees
| JFNNX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| JFNNX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| JFNNX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 32.00% | 0.00% | 238.00% | 30.37% |
JFNNX - Distributions
Dividend Yield Analysis
| JFNNX | Category Low | Category High | JFNNX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.51% | 0.00% | 6.24% | 5.66% |
Dividend Distribution Analysis
| JFNNX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | SemiAnnual | Annual |
Net Income Ratio Analysis
| JFNNX | Category Low | Category High | JFNNX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.09% | -2.54% | 1.85% | 38.82% |
Capital Gain Distribution Analysis
| JFNNX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 06, 2024 | $0.353 | OrdinaryDividend |
| Dec 06, 2024 | $1.596 | CapitalGainShortTerm |
| Dec 06, 2024 | $2.119 | CapitalGainLongTerm |
| Dec 07, 2023 | $0.152 | OrdinaryDividend |
| Dec 07, 2023 | $2.852 | CapitalGainLongTerm |
| Dec 20, 2022 | $0.273 | OrdinaryDividend |
| Dec 20, 2021 | $6.914 | OrdinaryDividend |
| Dec 17, 2020 | $5.657 | OrdinaryDividend |
| Dec 17, 2019 | $0.585 | OrdinaryDividend |
| Dec 17, 2019 | $3.322 | CapitalGainLongTerm |
| Dec 18, 2018 | $1.616 | CapitalGainShortTerm |
| Dec 18, 2018 | $5.107 | CapitalGainLongTerm |
JFNNX - Fund Manager Analysis
Managers
Andrew Acker
Start Date
Tenure
Tenure Rank
May 01, 2007
15.09
15.1%
"Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 23 years of financial industry experience."
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |